In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Danaher acquires GE Life Sciences' biopharma business for $21.4bn

Executive Summary

Danaher Corp. agreed to acquire the biopharma business (instruments, consumables, and software supporting research, discovery, process development, and manufacturing workflows of biopharmaceutical drugs, vaccines, and cell therapies) of GE Healthcare's GE Healthcare Life Sciences division for $21.4bn ($21bn in cash and $400mm for the assumption of pension liabilities), or about 17 times the biopharma unit's expected 2019 EBITDA.
Deal Industry
  • Contract Research, Toxicology Testing-CRO
  • Research, Analytical Equipment & Supplies
  • Services
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Synthesis Technologies, Production Processes
    • Drug Discovery Tools
      • Genomics-Proteomics
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies